Entities

Systems biology specialist; Seoul National University professor with earlier POSTECH appointments and an MIT chemical engineering doctorate. Listed on the company’s published scientific advisory board; advisory affiliation is distinct from employment.

Temasek investment professional focused on industrial, clean-energy, water and waste businesses.

Appointed February 6, 2025. Life sciences entrepreneur with Harvard MD and MIT biological engineering doctorate; contributed to founding Moderna and other life sciences companies. Advisory affiliation is distinct from employment.

Co-CEO of Bertis, a breast cancer surgeon and clinical proteomics advocate; current leadership also confirmed in the September 2026 company announcement.

Leads technology development, intellectual property and technical partnerships from research through deployment.

University of Calgary chemistry professor listed among Svante’s advisers.

Founded Membrion in 2016 and leads commercial deployment of its industrial wastewater technology.

Published name 권희충. Part-time independent director since March 2022; also CEO of GenCellmed. Holds a Kangwon University biology doctorate and has experience in regenerative medicine and gene/cell therapy research. Creation name is a research transliteration.

Company-published role in its May 18, 2023 announcement. Bertis does not expose a complete current management directory; this dated role has no departure or replacement identified in the reviewed primary sources.

Clinical research specialist and medical oncologist at UCSF, with prior Johns Hopkins, Emory and Yonsei training. Listed on the company’s published scientific advisory board; advisory affiliation is distinct from employment.

Company-published role in its June 25, 2024 announcement. Bertis does not expose a complete current management directory; this dated role has no departure or replacement identified in the reviewed primary sources.

Protein chemistry specialist; Seoul National University biological sciences assistant professor and former Institute for Basic Science RNA research team leader, with an SNU chemistry doctorate. Listed on the company’s published scientific advisory board; advisory affiliation is distinct from employment.

Published name 임종선. Finance executive since September 2021 and registered inside director since October 2025; previously CFO and internal accounting officer at Caregen and a CPA at PwC Samil. Creation name is a research transliteration.

Published name 임주현. Auditor since March 2024, separately classified from directors. Professor of tax accounting at Baewha Women’s University; previously auditor at Medit and CPA at PwC Samil. Creation name is a research transliteration.

Company-published role in its July 12, 2023 announcement. Bertis does not expose a complete current management directory; this dated role has no departure or replacement identified in the reviewed primary sources.

Water-treatment sales leader with experience across Latin America and other international markets.

Chevron executive with experience in downstream operations, capital projects, engineering and business performance.

Chemical and process engineering leader responsible for plant engineering, technology packaging and commercial deployment.

Climate Investment global managing director leading venture investment; previously held roles at 40 North, DBL and VantagePoint.

Advises on energy transition and corporate finance.

Surgical oncology specialist at Yale and Smilow Cancer Hospital, including breast program clinical leadership. Listed on the company’s published scientific advisory board; advisory affiliation is distinct from employment.

Leads production planning and execution, including operational safety, quality, efficiency and delivery.

Leads pilot commissioning and controls improvements while supporting customers and mentoring engineers.

Leads engineering and integration of carbon-capture products, demonstration systems and performance validation equipment.

Chartered accountant leading finance, accounting and internal controls, with experience across industrial sectors.

Oil-industry and downstream-sector adviser with four decades of experience.

Coordinates cross-functional strategy, operations and execution as Membrion scales.

Engineering and operations leader overseeing development and delivery of carbon-capture filters and rotary contactors.

Leads product and process development, manufacturing, supply chain and operational readiness for filters and rotary contactors.

Co-founder and chairman of the Roda Group, investing in climate, natural-resource and low-carbon technologies.

Leads membrane development and in-house water analysis and helps translate research into field products.

LC-MS specialist; chemistry professor and Genetic Protein Research Center director at Korea University, with a Caltech physical chemistry doctorate. Listed on the company’s published scientific advisory board; advisory affiliation is distinct from employment.

Published name 김상균. Full-time unregistered executive, not a board member, appointed May 2025. Previously held corporate management, investment and finance roles at Genome & Company, Nexon Korea, Samsung Fire & Marine, Socius PE and PwC Samil. Creation name is a research transliteration.

Company-published role in its May 16, 2024 announcement. Bertis does not expose a complete current management directory; this dated role has no departure or replacement identified in the reviewed primary sources.

Corporate and commercial lawyer with previous legal leadership in maritime, energy and financial services.

Leads project development and capital deployment with experience in energy and infrastructure financing.

Founder of Rznomics; the June 2026 issuer filing identifies him as CEO and an inside director. Professor of Life Convergence Engineering at Dankook University, with a Cornell doctorate and earlier research at Duke and Memorial Sloan Kettering.

Co-CEO of Bertis, leading development and commercialization of proteomics-based precision medicine technologies; current leadership also confirmed in the September 2026 company announcement.

Published name 한승렬. Research executive with the company since August 2017; doctorate from Dankook University and former senior researcher at the Next Generation Omics Institute. Creation name is a research transliteration.

Published name 김시윤. Part-time independent director appointed April 2026; associate professor at Konkuk University College of Veterinary Medicine and independent director of Cellames. Holds a CHA University biomedical science doctorate. Creation name is a research transliteration.

Develops membranes and processes for complex applications, drawing on materials science and electrochemistry.

Ecotopia Consulting founder and former Barclays investment banker focused on cleantech and social impact.

Company-published role in its June 25, 2024 announcement. Bertis does not expose a complete current management directory; this dated role has no departure or replacement identified in the reviewed primary sources.

Published name 홍성우. Development executive since December 2019; previously worked in pharmaceutical development at CJ CheilJedang, Otsuka Pharma Korea and Boryung. Creation name is a research transliteration, not a claimed official Latin spelling.

Finance and corporate-development leader with experience at Egis, WSP and AtkinsRéalis.

Leads operations with a focus on treatment delivery, quality, safety and customer outcomes.

Human-resources leader supporting organisational growth and employee development.

Company-published role in its October 20, 2025 announcement. Bertis does not expose a complete current management directory; this dated role has no departure or replacement identified in the reviewed primary sources.

Works on electrochemical water treatment, membrane performance and resource recovery.

Materials chemist leading sorbent development, with research experience in metal-organic frameworks and industrial carbon capture.

Breast surgery specialist; department and breast centre leadership at Singapore General Hospital, National Cancer Centre Singapore and SingHealth Duke-NUS. Listed on the company’s published scientific advisory board; advisory affiliation is distinct from employment.

Machine learning specialist and professor of Genome Sciences and Computer Science and Engineering at the University of Washington; UC San Diego doctorate in computer and cognitive science. Listed on the company’s published scientific advisory board; advisory affiliation is distinct from employment.

Jan Hardorp is published by re.Mind Capital as co-founder; general partner, investing in mental and neurological health. His current neurocare supervisory-board biography describes earlier work founding the payments business bezahl.de and roles at Merrill Lynch, McKinsey, Ströer and Waterland, with education in business administration and international economics.

Joao Barbosa da Silva is published by re.Mind Capital as investment associate, investing in mental and neurological health. Primary 2026 neuroscience conference programs and his self-published professional profile corroborate his continuing re.Mind investor affiliation.

Max de Vere is published by re.Mind Capital as co-founder; general partner, investing in mental and neurological health.

Elev8.vc is a Singapore-based early-stage venture capital firm backing deep-tech companies in artificial intelligence, quantum and other complex computing, robotics, advanced materials, smart mobility and medical technology. It helps technical founders commercialize research through capital, industry relationships and operating support, connecting Singapore-centered startups with markets and networks across Asia, Europe and North America. Its Ignite program supports the regional technology ecosystem.

Andrea is involved in the sourcing and evaluation of deals, due diligence, and the preparation of investment proposals for the fund’s investment decisions.

Andy is a General Partner at Wavemaker Partners.

Belle manages a selection of portfolio companies, conducting portfolio tracking and analysis under the Portfolio Management Team.

Camille manages a selection of portfolio companies under the Firm’s Portfolio Management Team (PMT).

Chris is involved in sourcing and evaluating deals, conducting due diligence, and preparing investment proposals to support the fund’s investment decisions..

Chyn Chyi supports financial reporting, budgeting, forecasting, and liaising with external auditors and tax agents.

Danika joined Wavemaker Partners in 2026 and is one of the firm’s Investment Principals.

Dom supports the Finance Team at Wavemaker Partners..

Eric is a Co-Founder and General Partner of Wavemaker Partners.

Evelyn is an Executive Assistant at Wavemaker Partners, she also helps with managing Wavemaker events..

Hannah obtained her Bachelor’s degree in Psychology at Ateneo de Manila University, where she developed her passion for creating solutions and assessment tools that help organizations with screening and performance management, backed by psychology-driven principles.

Harumi is the Office Manager at Wavemaker Partners, leveraging extensive experience in operations management and customer service across diverse hospitality markets in Peru, the US, Dubai, and Singapore.

Singapore capital-markets and technology lawyer supporting Wavemaker’s legal matters. Previously advised on IPOs before moving to in-house counsel roles. Distinct from the US venture-firm finance executive of the same name.

Janelle conducts ESG due diligence for new and follow-on investments for Wavemaker Ventures.

Joel joined Wavemaker Partners in 2016.

Jum is passionate about crafting narratives and telling meaningful stories.

Junius is involved in sourcing and evaluation of deals, due diligence, and the preparation of investment proposal for the fund’s investment decisions.

Justus oversees compliance, regulatory matters, and risk management at Wavemaker.

Charlie supports value creation at Wavemaker Partners through strategic partnerships, founder programs, and ecosystem engagement.

Mac oversees Finance at Wavemaker.

Mandy is Executive Assistant at Wavemaker Partners.

Manuel oversees Wavemaker’s Portfolio Management Team (PMT) and Information Systems (IS).

Marella specializes in providing communications support for Wavemaker and its portfolio companies.

Paolo is involved in the sourcing and evaluation of deals, due diligence, and the preparation of investment proposals for the fund’s investment decisions. Prior to joining Wavemaker, he was part of the business development team at the Professional Fighters League, where he focused on data strategy, geographic expansion, app development, and other IP-related verticals.

Paul Santos is the Co-Founder and Managing Partner of Wavemaker Partners, Southeast Asia’s leading VC firm investing in early-stage Enterprise, Deep Tech, and Sustainability startups.

Prior to Wavemaker, Phuong was one of the founding members of Vietnam’s local VC VinaCapital Ventures, where she sourced, executed, and added value to Seed and Series A investments.

Rachel leads strategic projects and supports the organisational development of Wavemaker.

Sam manages Wavemaker’s databases and systems under the Portfolio Management Team, creating automations and process improvements that enable seamless, cross-functional workflows across Investment, IR, and Comms Teams.

Shannon is a Senior Associate at Wavemaker Partners, focused on investments across Singapore, Malaysia, Australia, and New Zealand.

Shiv Choudhury is one of the Co-Founders of Growsari and a Partner at Wavemaker.

Tiffany helps to build the teams at Wavemaker and its portfolio companies.

Vasundhara is focusing on building relationships with investors and corporates.

Wan En is involved in the sourcing and evaluation of deals, due diligence, and the preparation of investment proposals for the fund’s investment decisions.

Wen Ge is an investor at Wavemaker Partners, where he focuses on growth-stage opportunities.

Wendy supports the finance team at Wavemaker Partners.

Wenshan practiced as an intellectual property and tech lawyer for 5 years before making the shift in-house as a dedicated legal counsel.

Xue heads the investment team for Black Kite Capital, a Singapore-based single family office.

Yanna covers the Philippine market on behalf of the firm.

Yasmin works closely with the Investor Relations team to ensure that fundraising, and other cross-functional projects run smoothly..

Ysabela is Wavemaker’s resident ESG Senior Associate and looks after the development and integration of the Firm’s ESG Practice.

Monteris Medical develops MRI-guided, robotically controlled laser ablation technology for minimally invasive neurosurgery. Its NeuroBlate System combines laser delivery probes, stereotactic positioning, thermal monitoring and planning software to ablate intracranial soft tissue. Surgeons use it for selected brain tumors, radiation necrosis and epileptic foci; the device is a surgical tool rather than a disease-specific drug or guaranteed cure. NeuroBlate received FDA 510(k) clearance in 2013, with subsequent product updates, and is used across North American hospitals. Founded in Winnipeg in 1999, Monteris has its corporate headquarters in Minnetonka, Minnesota and technology operations in Winnipeg. President and CEO Marty Emerson leads seven publicly named executives, with an eight-member board. The company closed $28 million in Series E equity in March 2026, separately refinancing debt through a Trinity Capital credit facility. A 2025 collaboration with Symphony Robotics explores an AI-driven micro-robotic brain-ablation platform; that partnership is not evidence of a completed investment or universal regulatory clearance.

Birchview Capital LP is a Massachusetts and Vermont healthcare investment manager, combining medical and life-science diligence with quantitative research, AI, natural-language processing and machine learning. The firm invests in public and private healthcare companies intended to address unmet clinical needs, and manages private funds and separately managed accounts. Its current public team spans healthcare investing, quantitative strategies, investment operations and finance. The firm began operations in 2014 and has offices in Boston and Burlington. Birchview’s neuroscience exposure includes equity investment in Monteris Medical, developing minimally invasive brain surgery technology. It is a distinct US investment adviser from the unrelated Ontario acquisition firm at birchviewcapital.ca. Regulatory assets under management and public securities portfolio values are not fund-closing amounts.

CarbonCure Technologies supplies hardware and software that inject captured carbon dioxide into concrete during mixing. The carbon dioxide reacts to form calcium carbonate and becomes permanently embedded, allowing producers to reduce cement use while maintaining concrete performance. Its equipment connects with concrete-plant batching systems, remote telemetry and the myCarbonCure producer platform; the company also generates carbon credits associated with its carbon-utilisation process.

Liquid Wind develops commercial eFuel production facilities that combine renewable electricity, green hydrogen and captured biogenic carbon dioxide to produce eMethanol. It standardises plant design and uses digital twins to replicate facilities, working with industrial partners, carbon-dioxide suppliers and fuel buyers. Its projects target lower-carbon fuel supply for shipping and other industries that are difficult to electrify.

Previously senior software engineer at Faculty.

Co-founder of Ogment, developing AI agents and integrations for business systems.

Blue Earth Capital director investing in the low-carbon transition, with previous roles at Inherent Group and Orange Capital.

Leads commercial and customer-success activities across Asia Pacific, Europe and the Middle East; joined CarbonCure in 2014.

Previously tech lead at Raft.

Previously chief of staff at Allermuir Capital and worked at Morgan Stanley.

Breakthrough Energy Ventures partner and technology entrepreneur, formerly chairman and CEO of CoalTek.

Founded Liquid Wind and leads the company’s eFuel facility development business.

Previously invested in enterprise software and applied AI at MMC Ventures, then served as COO of Sedna.

Construction-materials executive who joined the board on October 1, 2026; previously led businesses at Amrize and Lafarge Canada.

Concrete engineering specialist leading product development, with experience in reinforced concrete and low-carbon materials.

Founding engineer at Ogment, building AI agents that operate in Slack and connected business tools.

Previously solutions engineer at Raft and Chattermill.

Previously software engineer at Palantir.

Uniper innovation manager who serves on Liquid Wind’s published board.

Human-resources leader responsible for organisational development, employee experience and people strategy.

Finance executive and chartered professional accountant; served as interim CEO before becoming president in April 2026.

HYCAP investment principal who serves on Liquid Wind’s published board.

Previously senior vice-president of customer operations at Sedna and worked at Convelio.

Leads marketing, strategic communications and external engagement, drawing on a background in climate communications and broadcast journalism.

Previously market pricing optimisation analyst at IAG Cargo.

Construction-materials executive elected board chair in May 2026; also serves as a senior adviser to CRH’s CEO.

Member of the Ogment team, working on the company’s AI agent product.

Leads regional business growth and concrete-producer adoption, following a career at Command Alkon.

Founded CarbonCure in 2012 and served as CEO until 2025; now leads XLYNX Materials while continuing to advise CarbonCure.

Commercial leader helping concrete producers adopt and expand CarbonCure systems; previously worked at Command Alkon.

Previously principal engineer at Kular.

Isometric chief science officer and former Shopify sustainability leader with experience in carbon-removal standards and purchasing.

Previously head of professional services at Sedna and worked at Flintfox.

Previously worked at Palantir, Oracle Labs, ETH Zurich, Meta and Unlikely AI.

Co-founder and CEO of Ogment, building AI agents for accounting and business workflows.

Previously head of business at Pactio and worked at McKinsey.

Previously technical lead at Unlikely AI and worked at Hedgehog.

Building-materials executive appointed CEO in April 2026; previously led integration at CRH and held roles at Lafarge and Holcim.

Diego Garcia is an Associate at Pallas Ventures, applying national security, policy and communications experience. He previously advised the CEO of the US International Development Finance Corporation and executives of a Fortune 500 defense contractor. As Special Assistant to the Under Secretary of Defense for Research and Engineering, he supported the establishment of the Pentagon Office of Strategic Capital. He graduated from Harvard College.

Hemanth Varghese is a healthcare executive who served as President and Chief Operating Officer of Venus Concept before departing on March 28, 2025. His earlier company roles included Chief Business Officer and oversight of medical device innovation. The issuer explicitly named him as a personal common-stock participant in its November 18, 2022 financing; this investment is separate from employer investments.

S. Tyler Hollmig is a dermatology professor and director of dermatologic surgery and laser/cosmetic dermatology at UT Austin Dell Medical School. He trained at UT Southwestern, Stanford and the Medical University of South Carolina. Venus Concept named him as an independent director and personal common-stock financing participant in November 2022; historical board status is not assumed to remain current after the 2026 take-private.

Zak Enzminger is an Associate at Pallas Ventures, with a background in writing, strategy, marketing and strategic communications. He focuses on the startup and venture ecosystem surrounding national security. He holds a BA in Middle East Studies and Archaeology from Brown University and an MA from Johns Hopkins SAIS in Strategy, Cybersecurity and Statecraft.

Artemis Capital Partners is a Boston private equity manager that buys and builds manufacturers of specialised industrial technologies. It invests in engineered products used in aerospace, defence, life sciences and semiconductors, including analytical instruments, radio-frequency and microwave components, testing and measurement, thermal management, optics and photonics, and diagnostics. Artemis supplies capital, operational guidance and acquisition support to help established technical businesses grow.

Graduate Ventures invests at pre-seed and seed in Dutch university-connected AI, deep-tech, healthcare and climate startups. It combines capital with practical support from experienced entrepreneurial alumni, fund professionals and student investment teams. Its pre-seed programme supports early validation; its seed funds help companies develop products, gain initial customers and prepare for Series A. Established in 2021 by alumni of TU Delft, Erasmus University Rotterdam and Erasmus MC, the platform now works with universities and university medical centres across the Netherlands. Graduate Ventures Fund Management B.V. manages Graduate Ventures Fund II Coöperatief U.A.

Pulse Fund is a Los Angeles venture firm investing in early-stage climate technology companies across energy transition, infrastructure, food and agriculture, and mobility. It looks for technologies whose commercial effects connect these sectors, including advanced materials, electrification, AI-supported infrastructure and environmental monitoring. The firm supports portfolio companies with strategic guidance, operating expertise, governance and access to additional financing, and frequently takes board roles. Its collaboration with NASA’s Goddard Space Flight Center connects companies to publicly available Earth-observation data, modelling and climate technology.

Seed Capital is a Copenhagen venture firm backing Nordic technology founders from seed through early Series A and supporting companies through later financings and exits. It focuses on fintech, cybersecurity and resilience, and AI-driven business software. The firm works with a concentrated portfolio, helping founders develop go-to-market plans, strengthen teams and boards, refine unit economics and raise international follow-on capital. Its Fund V expands its longstanding Danish investment strategy across the Nordic region. Legal and fund scope: the retained profile represents the published Seed Capital investment platform, with fund-specific managers and vehicles distinguished. The site privacy notice identifies CVR37140279; signed accounts separately identify legacy Seed Capital Management I/S CVR28293089 managing DenmarkII, ManagementIII serving DenmarkIII and its separate2021Growth vehicle, and ManagementIV CVR41370629 serving DenmarkIV CVR41500727. FundV has its own manager and GP agreement; those entities are not collapsed into one cash subscriber. Christian Brøndum’s current managing-partner role is explicitly for FundV; Ulla and Lars retain their published partner roles and dated legacy management capacities. Nine current named people appear in the directory. FundV’s finalEUR130M close supersedes its May2025DKK500M firstclose, without addinganotherfund; the earlier149Mpaid-in snapshot is a partialcall, not totalfinalsize. FundIV’s ownpublishedEUR140M raise is distinct from NAV and manageraccounts. Older funds’ disclosed commitments are qualified separately where originalcashclosingproof is unavailable. Approximate500M aggregatecapital is not anotherfund or allocatedcompanycheck.

Venture lawyer supporting investment transactions, fund formation and ESG reporting. Anne Cathrine Wilhjelm — Attorney and partner specialising in technology investment transactions, fund formation, M&A and ESG reporting. Her published experience spans all five flagship funds and Danish/international venture transactions.

Investment-fund lawyer and regulatory adviser with experience in private fund formation and governance.

Early-stage investor focused on fintech, vertical software and marketplaces. Chris Porsgaard — The current directory and individual header identify him as Partner; an older biography paragraph still says Principal. He focuses on fintech, vertical SaaS and marketplaces, with prior venture-building at Rainmaking and engineering studies at DTU and Stanford.

Former Planday CEO with experience scaling software businesses, corporate consulting and Nordic technology investing. Christian Brøndum — Managing partner of FundV and former Planday chief executive, leading its international growth and 2021 exit to Xero. He previously worked at IBM and in management consulting and holds a Copenhagen Business School master’s degree.

Software entrepreneur and investor with experience building security and enterprise software companies, including Humio. Geeta Schmidt — General partner and former Humio co-founder/chief executive. She served at CrowdStrike after its 2021 acquisition of Humio, joined Seed in2024, and previously worked at Sun Microsystems and Trifork.

Gema Robles is Director at Pallas Ventures. She served for 21 years as a US Army Officer and Aviator, flying UH-60 Blackhawks, commanding a battalion in the 101st Airborne Division and serving as aide-de-camp to the Vice Chairman of the Joint Chiefs of Staff. She subsequently worked in private equity, strategic business planning, financial modeling and risk management. She holds a BS in Business Administration with a Finance concentration from Millersville University.

Investment and operations professional supporting Pulse Fund’s climate investment work.

Finance partner responsible for fund financial management, investor relationships and portfolio-company financial structures. Jakob Fuglede Nielsen — CFO and partner, joining in2006 and overseeing fund financial management, LP relations and portfolio capital structures. He previously worked in finance, project evaluation and M&A at Ørsted.

Architect and climate innovator experienced in sustainable communities and environmental initiatives.

Venture and private-equity finance leader with experience in fund reporting, audits, tax and operations.

Investor focused on fintech, enterprise software and SaaS, with investments including Lunar and Templafy. Lars Andersen — General partner focused on fintech and enterprise software, including Templafy and Lunar. He co-founded and led Columbus IT Partner and other technology businesses and studied marketing/management inAarhus.

Climate technology investor and venture builder with sustainability and financial-services experience.

Investment professional with finance training and experience in strategy consulting, private equity and fintech. Rikke Kjær Damgaard — Investment manager with Copenhagen Business School finance/business degrees, previous BCG private-equity diligence work, and experience at A.P. Moller Holding, Deloitte and fintech YouLend. She joined inMay2025.

Climate investor and entrepreneur supporting businesses across energy, infrastructure, food and mobility.

Early-stage investor focused on climate technology, SaaS and deep technology. Tine Lindgreen — Partner focused on climate technology, SaaS and deep technology. She previously worked in investment banking, Ageras business development and Vækstfonden, and holds a Copenhagen economics/finance master’s degree.

Founder and venture investor who has led Seed Capital across multiple funds and technology company investments. Ulla Brockenhuus-Schack — Founder and general partner, establishing Seed in2004. Her previous career includes McKinsey, Egmont and Nordisk Film innovation work and entrepreneurship; she holds a Columbia MBA. Fund-specific legacy managing capacities are distinguished from current FundV leadership.

Tony DeMartino is a Founding Partner of Pallas Ventures, identified as Anthony G. DeMartino in the fund's SEC filing. He previously served as Deputy Chief of Staff to the Secretary of Defense and Chief of Staff to the Deputy Secretary of Defense, following more than 20 years as a US Army Infantry officer. His published biography describes his advisory work with AI-validation company CalypsoAI and the Center for a New American Security. He holds master's degrees from George Mason University and the School of Advanced Military Studies and a BS from Washington and Lee University.

Richard Spencer is Managing Director of Pallas Ventures. He formerly served as the 76th Secretary of the Navy and as Managing Director of Fall Creek Management LLC, Vice Chairman and CFO of Intercontinental Exchange, and President of Crossroads Investment Management LLC. A Rollins College graduate, he served as a Marine Corps helicopter pilot. SEC filings identify Richard V. Spencer as managing director of Pallas Ventures Fund LP.

Sally Donnelly is a Founding Partner of Pallas Ventures. Her public service included Senior Advisor to the Secretary of Defense, Director of the Washington Office for the Commander of US Central Command, and Special Assistant to the Chairman of the Joint Chiefs of Staff. She previously founded a Washington consulting firm and worked for more than 20 years at Time Magazine. She holds a master's degree from the London School of Economics and a BA from Hollins College.

Healthcare growth-equity investment firm founded in 1985, formerly known as Essex Woodlands. Its registered investment adviser is Essex Woodlands Management, Inc., with Essex Woodlands Services Co., Inc. as a relying adviser. The firm invests in revenue-generating pharmaceutical, medical-technology and technology-enabled healthcare businesses in the United States and Europe, with offices in New York, London and Houston. Its portfolio includes robotic medical devices, AI-enabled pathology, metabolomics, nerve regeneration and healthcare data services. Evis Hursever is CEO, Petri Vainio is Executive Chairman and Scott Barry is COO. Its public directory lists 15 current investment, operating and advisory members, with two additional managers of legacy venture funds. Operating Partners and Senior Advisors are advisory affiliations and do not by themselves establish employee or fund-partner status. Fund 1 and Fund 2 reported fully sold SEC offerings of USD543.1 million and USD746.325 million respectively; Fund 3 reported USD570.65 million sold in December 2022, without an independently verified final close. Parallel funds and former fund names are recorded within the same fund family to avoid double counting.

Operating Partner at EW Healthcare Partners since 2025, also identified as Andrew J. Thomson. He previously held senior leadership roles at Thermo Fisher Scientific, including its EMEA businesses, corporate accounts and marketing. He joined Grundium’s board in 2023 and Germfree’s in 2025 and chairs Grundium. He studied economics at Queen’s University. The firm’s legal disclaimer does not treat this advisory title as evidence of employee, principal or fund-partner status.

Operating Partner at EW Healthcare Partners since 2019. He previously led Entellus Medical through its acquisition by Stryker. His published portfolio responsibilities include executive chair of BioTissue and board work in medical technology. He studied aerospace engineering at Missouri-Rolla and earned an MBA at Cornell. The firm’s legal disclaimer does not treat this advisory title as evidence of employee, principal or fund-partner status.

Operating Partner at EW Healthcare Partners since 2017. He founded and led specialty pharmaceutical businesses including EUSA Pharma and Zeneus, and later founded Izana Bio and Akaza Bio. His earlier pharmaceutical career included Merck and Bristol Myers Squibb. He studied pharmacology at Aberdeen and business administration at Durham, and received a CBE for contributions to healthcare. The firm’s legal disclaimer does not treat this advisory title as evidence of employee, principal or fund-partner status.

CEO of EW Healthcare Partners since 2024. She joined in 2011 and became a managing director in 2019. Her healthcare investments include Cognate Bioservices, Grundium, Germfree, Boiron and Ascend Advanced Therapies. Before EW she worked in life-sciences consulting at LEK and healthcare investment banking at Merrill Lynch. She holds a Macalester undergraduate degree and a University of Pennsylvania doctorate.

Senior Principal at EW Healthcare Partners, which he joined in August 2017. He previously worked on European and US life-sciences investments at Novo Holdings and began in investment banking at J.P. Morgan in London. He studied business administration and intellectual capital management at the University of Gothenburg.

Chief Financial Officer and Chief Compliance Officer of EW Healthcare Partners since 2023. His earlier experience includes CFO and compliance responsibilities at real-asset and private-equity firms, with roles at Revelstoke, Saybrook and Baupost. He studied at Saint Joseph’s University.

Operating Partner at EW Healthcare Partners since 2013, after joining the firm in 2006. His published board work includes Enercon Technologies, Bioventus and TELA Bio. He previously served as Guidant’s chief operating officer, overseeing its cardiovascular-device businesses, and held earlier international operating roles. His education includes business engineering at the University of Leuven and an MBA at Stanford. The firm’s legal disclaimer does not treat this advisory title as evidence of employee, principal or fund-partner status.

Managing Director responsible for EW’s legacy Essex Woodlands Funds IV through VIII. He joined in 1998 after experience at ARCH Venture Partners and operating HealthQual before its sale. He studied at the University of Chicago, where he also earned an MBA. This published role concerns legacy funds rather than management of the current growth-equity strategy.

Managing Director responsible for EW’s legacy Essex Woodlands Funds VI through VIII. He joined in 1999 according to the firm’s biography. His earlier career included scientific work at Genzyme and co-founding Seed-One Ventures. He holds an MIT undergraduate degree and Harvard doctorate. This published role concerns legacy funds rather than management of the current growth-equity strategy.

Vice President at EW Healthcare Partners since joining in 2022. She previously worked in Barclays’ healthcare investment banking group on pharmaceutical, biotechnology and services transactions and interned at Carlson Capital. She studied economics and mathematics at the University of Pennsylvania.

Co-founder of EW Healthcare Partners, previously Essex Woodlands, and chair of the investment committees for Funds 1, 2 and 3. His healthcare investments have included Abiomed, ATS Medical, BioForm Medical and LifeCell. The firm publishes board positions at MiMedx, Prolacta and Bioventus. He studied at Louisiana State University and earned an MBA at the University of Houston. SEC filings identify the same individual as Martin P. Sutter.

Executive Chairman of EW Healthcare Partners and chair of its executive committee. He joined the firm in 2004 after twelve years as a Sierra Ventures general partner. His healthcare investing experience includes pharmaceutical and medical-device businesses, and his published board affiliations include Grundium and Laboratoires Majorelle. He earned medical and doctoral degrees in Helsinki and an MBA at Stanford.

Associate at EW Healthcare Partners since joining in 2023. He previously worked at Cain Brothers on healthcare mergers, acquisitions and financial advisory work. He holds a finance master’s degree from Vanderbilt and studied biochemistry at Furman.

Senior Advisor to EW Healthcare Partners since 2021, following managing-director responsibilities after joining in 2006. His healthcare investments included ProteinSimple, Corium, EyePoint and Elusys, and the firm publishes a Suneva board affiliation. He studied at Williams and earned an MBA at Columbia. The firm’s legal disclaimer does not treat this advisory title as evidence of employee, principal or fund-partner status.

Principal at EW Healthcare Partners, which he joined in 2021. His published responsibilities include observing Enercon Technologies’ board. He previously invested at Copley Equity Partners and Crestview Partners. He holds an Amherst undergraduate degree and Stanford MBA.

COO of EW Healthcare Partners since 2024, having joined in 2006 and become a managing director in 2012. His published board work includes Metabolon and Venus Concept. He previously led pharmaceutical mergers, acquisitions and collaborations at Novartis and worked in healthcare corporate finance at Century Capital and KPMG. He studied at Wesleyan and earned an MBA at New York University.

Pallas Ventures is the venture investment arm of national-security advisory firm Pallas Advisors, launched in May 2020. It invests in companies developing dual-use technologies with commercial and national-security applications and supports their growth in government and defense markets. Its published typical investments range from $500,000 to $1.5 million, through cash purchases or equity received for services; those ticket sizes are not fund size. Portfolio areas include AI and cybersecurity, space logistics, hypersonic aircraft, radioisotope power and environmental sensing. The current public team comprises Richard Spencer, Sally Donnelly, Tony DeMartino, Gema Robles, Zak Enzminger and Diego Garcia. SEC adviser records identify Pallas Ventures GP LLC, CRD311314, as the legal adviser and general partner of Pallas Ventures Fund LP, a Delaware venture-capital vehicle formed in 2020. A March 2021 Form D reports $1,075,004 of fund interests sold to five investors in an indefinite offering, rather than a verified final fund close. The advisory consultancy and venture investment business are separate functions of the Pallas enterprise.

Elizabeth Fitzgerald is Head of Marketing at M12, Microsoft’s corporate venture capital arm. The firm’s current team directory and individual biography identify this role. M12 invests in early-stage software companies across AI, security, cloud infrastructure and deep technology.

David Lai is Portfolio Development at M12, Microsoft’s corporate venture capital arm. The firm’s current team directory and individual biography identify this role. M12 invests in early-stage software companies across AI, security, cloud infrastructure and deep technology.

Puneet Tandon is Senior Portfolio Development Manager at M12, Microsoft’s corporate venture capital arm. The firm’s current team directory and individual biography identify this role. M12 invests in early-stage software companies across AI, security, cloud infrastructure and deep technology.

Marion Desmazières works in Portfolio Development at M12. Her primary biography identifies experience supporting startups and previous work with the Amazon Alexa Fund, including conversational AI.

Marty Collins is Head of Portfolio Development at M12. Her background includes Microsoft consumer product launches, digital transformation work at Zillow and building an ecommerce business using machine learning.

Anthony Sims is Business Administrator at M12, Microsoft’s corporate venture capital arm. The firm’s current team directory and individual biography identify this role. M12 invests in early-stage software companies across AI, security, cloud infrastructure and deep technology.

Jenelle Mezzetti is Executive Business Administrator at M12, Microsoft’s corporate venture capital arm. The firm’s current team directory and individual biography identify this role. M12 invests in early-stage software companies across AI, security, cloud infrastructure and deep technology.

Maggie John works in Strategy and Operations at M12, with her primary biography identifying responsibility for the function. Her previous experience includes market development at Convoy. She studied chemical engineering at IIT and earned an MBA from Wharton.

Tero Collin is Head of Fund Operations and Strategy at M12, Microsoft’s corporate venture capital arm. The firm’s current team directory and individual biography identify this role. M12 invests in early-stage software companies across AI, security, cloud infrastructure and deep technology.

Brian Zhao is Investment Team at M12, Microsoft’s corporate venture capital arm. The firm’s current team directory and individual biography identify this role. M12 invests in early-stage software companies across AI, security, cloud infrastructure and deep technology.

Yuhang Zhang is Associate at M12, Microsoft’s corporate venture capital arm. The firm’s current team directory and individual biography identify this role. M12 invests in early-stage software companies across AI, security, cloud infrastructure and deep technology.

James Wu is a Partner at M12 in the Bay Area, investing in business and infrastructure software including DevOps, data science, fintech and cybersecurity. He previously invested at FTV Capital and worked at Jefferies, and earned an economics and accounting degree from UCLA. He is distinct from James Wu at First Round, the Duke graduate and AdaptiLab co-founder.

Tracy Liu is Senior Associate at M12, Microsoft’s corporate venture capital arm. The firm’s current team directory and individual biography identify this role. M12 invests in early-stage software companies across AI, security, cloud infrastructure and deep technology.

Jim Walsh is an Advisor at Stage 1 Ventures, based in Palo Alto. The firm invests in disruptive deep technology and science companies from seed through growth equity and supports portfolio businesses through its operating and advisory network.

Larry Paulson is an Advisor at Stage 1 Ventures, based in San Diego. The firm invests in disruptive deep technology and science companies from seed through growth equity and supports portfolio businesses through its operating and advisory network.

Ralph Rodriguez is an Advisor at Stage 1 Ventures, based in Naples. The firm invests in disruptive deep technology and science companies from seed through growth equity and supports portfolio businesses through its operating and advisory network.

Peter Lenke is a Managing Partner at M12. Before joining he led Atlassian Ventures and worked in corporate development at Twitter and Criteo, with earlier experience at SVB Capital.

David Mathews is an Advisor at Stage 1 Ventures, based in Dallas. The firm invests in disruptive deep technology and science companies from seed through growth equity and supports portfolio businesses through its operating and advisory network.

John Hartnett is an Advisor at Stage 1 Ventures, based in Los Gatos. The firm invests in disruptive deep technology and science companies from seed through growth equity and supports portfolio businesses through its operating and advisory network.

John Sheehan is an Advisor at Stage 1 Ventures, based in Ft Worth. The firm invests in disruptive deep technology and science companies from seed through growth equity and supports portfolio businesses through its operating and advisory network.

Lawrence King is an Advisor at Stage 1 Ventures, based in Dallas. The firm invests in disruptive deep technology and science companies from seed through growth equity and supports portfolio businesses through its operating and advisory network.

Mark Leidy is an Advisor at Stage 1 Ventures, based in St. Louis. The firm invests in disruptive deep technology and science companies from seed through growth equity and supports portfolio businesses through its operating and advisory network.

Michael Baum is an Advisor at Stage 1 Ventures, based in San Francisco. The firm invests in disruptive deep technology and science companies from seed through growth equity and supports portfolio businesses through its operating and advisory network.

Rod Randall is a Special Advisor at Stage 1 Ventures, based in Boston. The firm invests in disruptive deep technology and science companies from seed through growth equity and supports portfolio businesses through its operating and advisory network.

Susan Major is an Advisor at Stage 1 Ventures, based in San Diego. The firm invests in disruptive deep technology and science companies from seed through growth equity and supports portfolio businesses through its operating and advisory network.

Alfonso Carrillo is an Operating Partner at Stage 1 Ventures, based in Miami. The firm invests in disruptive deep technology and science companies from seed through growth equity and supports portfolio businesses through its operating and advisory network.

Michael Frank is an Operating Partner at Stage 1 Ventures, based in Boston. The firm invests in disruptive deep technology and science companies from seed through growth equity and supports portfolio businesses through its operating and advisory network.

Mike Courtney is an Advisor at Stage 1 Ventures, based in Dallas. The firm invests in disruptive deep technology and science companies from seed through growth equity and supports portfolio businesses through its operating and advisory network.

Scott Carmel is an Operating Partner at Stage 1 Ventures, based in Miami. The firm invests in disruptive deep technology and science companies from seed through growth equity and supports portfolio businesses through its operating and advisory network.

Shun Hagiwara is a Senior Associate at M12. His previous experience includes Emergence Capital, Fractal Software and L.E.K. Consulting, with a focus on AI and business software. He graduated from UCLA.

Joseph Pianelli is an Operating Partner at Stage 1 Ventures, based in Dallas. The firm invests in disruptive deep technology and science companies from seed through growth equity and supports portfolio businesses through its operating and advisory network.

Les Yetton is an Operating Partner at Stage 1 Ventures, based in Boston. The firm invests in disruptive deep technology and science companies from seed through growth equity and supports portfolio businesses through its operating and advisory network.

David Baum is a Managing Director of Stage 1 Ventures, based in Miami. He is also identified as managing partner and signatory of the affiliated investment adviser Stage 1 Managers LLC in its March2026 SEC filing. Portfolio-company leaders from ai.io, ViralGains and Talkmap describe his early investment support, business guidance and company-building assistance in the firm’s current public testimonials.

Jonathan Gordon is a co-founder and Managing Director of Stage 1 Ventures, based in Tampa. He co-founded the venture firm in January2006. His company-published biography in Kliken’s SEC offering memorandum describes experience building technology businesses across enterprise and systems software, semiconductors and instrumentation, from early stages through exits. He supports business development, sales channels, product development and intellectual property commercialization.

Todd Graham is Managing Partner at M12, Microsoft’s corporate venture capital arm. The firm’s current team directory and individual biography identify this role. M12 invests in early-stage software companies across AI, security, cloud infrastructure and deep technology.

Michelle Gonzalez is Microsoft Corporate Vice President and Global Head of M12. Her previous investment and operating roles include Google’s Area120, Comcast Ventures and IBM Ventures. She leads Microsoft’s venture arm and its work with founders.

Alan Du is a Partner at M12. He previously invested at PayPal Ventures and worked at Docker China and Revolution. His published biography identifies experience across AI, fintech and enterprise technology and degrees from UC Berkeley and Harvard Business School.

Cheryl Cheng is a Managing Partner at M12. She founded Vive Collective and previously served as a General Partner at BlueRun Ventures. Her background includes healthcare software investing. She holds degrees from Stanford and Kellogg.

Chief Scientific and Policy Advisor to Madryn Asset Management. She previously directed the US Centers for Disease Control and Prevention from 2021 to 2023, leading public health infrastructure and agency modernization work. Earlier she led the Infectious Diseases Division at Massachusetts General Hospital and was a professor of medicine at Harvard Medical School. Her manager biography also identifies a Carter Center board role; the Madryn role is an advisory position. Rochelle Walensky is an Isaac Health advisory-board member and a physician and public-health researcher. Harvard identifies her prior CDC leadership during2021–2023 and earlier leadership of infectious diseases at Massachusetts General Hospital. Her training includes an MD from Johns Hopkins and an MPH from Harvard.

Principal and Director of Finance of Madryn Asset Management, supporting portfolio investments, financial reporting, fundraising and investor relations. Previously he worked on venture portfolio operations and accounting at Innovation Endeavors, alternative investment fund auditing and healthcare valuations at KPMG, and risk advisory at PwC.

Senior Operations Associate of Madryn Asset Management. He supports the investment portfolio and financial reporting, fundraising and investor relations alongside the CFO and investment team. Previously an associate at PwC, auditing business processes in real estate investment trusts and insurance.

General Counsel and Chief Compliance Officer of Madryn Asset Management. He manages regulatory compliance and participates in operational and investment processes. Before joining the firm he advised private equity managers and registered investment advisers as a senior principal consultant at ACA Group, including two years as Madryn’s external consultant.

Vice President of Madryn Asset Management, working on healthcare investment sourcing, evaluation and management. Previously he worked in Bank of America Merrill Lynch’s Global Healthcare investment banking group on mergers and acquisitions and debt and equity transactions across healthcare services and medical devices.

Senior Associate of Madryn Asset Management, working on healthcare investment sourcing, evaluation and management. Previously an investment banking associate in Bank of America Merrill Lynch’s Global Healthcare group, focused on financing and mergers and acquisitions in healthcare services and life sciences.

Managing Director of Madryn Asset Management, working on sourcing, evaluating and managing healthcare investments. Before Madryn he was an analyst in Stifel’s healthcare investment banking group, supporting public and private financing and merger and acquisition transactions.

Partner of Madryn Asset Management, also referred to as Alexander Marcantonio in the manager’s public posts. He sources, evaluates and manages healthcare investments. His earlier career includes biopharmaceutical investing at Lombard Odier Asset Management, healthcare investing at Orchard View Capital and healthcare investment banking at Citigroup. Madryn identifies his promotion to partner in 2026. Alex Marcantonio is Board Member at Monteris Medical. He is a Managing Director at Madryn Asset Management.

Partner and co-founder of Madryn Asset Management, sourcing, evaluating and managing healthcare investments. Previously a partner at Visium Healthcare Partners and Paul Capital, he earlier held commercial and executive roles at Pfizer, American Home Products and Aventis and served as Cambrex president and CEO. Prior company board positions described in his manager biography are not automatically treated as confirmed current appointments.

Partner, Chief Operating Officer and Chief Financial Officer of Madryn Asset Management. He oversees accounting, tax, financial reporting and operations and participates in investment processes and the investment committee. Before Madryn he was controller at Snow Phipps Group, an operations associate at Siguler Guff and an auditor of private equity and hedge funds at Rothstein Kass.

Venture capital firm founded in January2006 and based in Coconut Grove, Miami, with managing directors David Baum and Jonathan Gordon. Stage1 backs disruptive deep technology and science companies from seed investments through growth equity. Its approach combines small seed investments and company-specific vehicles with support for business development, intellectual property and commercial growth, followed by larger investments in businesses that scale. Its current portfolio spans artificial intelligence, enterprise software, robotics, agriculture, cybersecurity, aerospace, nuclear batteries and biotechnology. The website lists two managing directors, five operating partners and twelve advisors, including one special advisor. Its affiliated investment adviser Stage1 Managers LLC, CRD313429, files the exact stage1ventures.com website and David Baum managing-partner signature in its March2026 SEC filing, which lists eleven private fund vehicles. Fund gross asset values and the website’s USD2 billion investment-proceeds statistic are distinct from announced final fund closes. Verified investments include Zeno Power’s May2025 USD50 million SeriesB and portfolio affiliations with Four Growers, JumpCloud, True Anomaly and Sail Biomedicines.

Eric Letourneau was appointed Venus Concept’s US sales vice president in May 2026, overseeing sales, practice development and sales training.

Jesus Alvarez-Quintero leads Venus Concept sales and general management for LATAM and EMEA, including EMEA sales execution, as announced in May 2026.

Rajiv De Silva became a transition special advisor to Venus Concept in September 2026 after serving as its CEO. He was one of the personal common-stock participants named in its November 2022 financing.

Anna Georgiadis leads human resources at Venus Concept. Her prior career at Loblaw combined HR and commercial responsibilities; she holds Toronto and Canadian HR qualifications.

Melissa Kang is Venus Concept’s chief product officer. Her background spans Allergan, Merz and Prollenium, with chemistry, business and accounting qualifications.

Michael Mandarello oversees legal affairs, operations and strategy at Venus Concept. He previously practiced corporate law at Osler and held in-house legal positions.

Ross Portaro leads commercial strategy and Venus Hair at Venus Concept. His healthcare sales background includes Candela, Lumenis and Ulthera; he studied commerce at Virginia.

Brad Oliver became CEO of Venus Concept on September 7, 2026. He previously led Lumenis Americas and trained in executive leadership at Harvard and Michigan.

Venus Concept Inc. is a Toronto-headquartered medical aesthetic technology company that markets itself as Venus Aesthetic Intelligence or Venus AI at venus.ai. This brand is the same issuer as Venus Concept, and is unrelated to Venus Aerospace. Its Delaware legal predecessor was incorporated as Restoration Robotics in 2002; the company adopted the Venus Concept name after its November 2019 merger with the operating Venus Concept Ltd. business. Its relevance to AI and deep technology comes from medical robotics, machine vision, AI algorithms and energy-based aesthetic devices. The company describes its AI.ME platform as robotic fractional skin resurfacing using machine vision and AI, and reported a US FDA 510(k) clearance for that indication in December 2022; claims about predictable results or worldwide treatment volumes are manufacturer statements, rather than independent performance findings. Its commercial range includes Venus NOVA, Versa and Versa PRO, Bliss and Bliss MAX, Viva and Viva MD, Legacy, Velocity, Epileve and AI.ME; current corporate releases also list NeoGraft and ARTAS iX hair restoration systems. In July 2026 it announced exclusive US/Canada distribution rights for HIRONIC Doublo 2.0. Brad Oliver became CEO on September 7, 2026, succeeding Rajiv De Silva, who moved to a transition Special Advisor role. The current directory publishes five executives; May and September 2026 issuer announcements additionally identify two sales leaders and board chairman Avinash Amin. Madryn-managed funds became sole owners following a March 30, 2026 short-form merger, separately from the company’s $1.5 million common-stock cash raise closed March 26. Historical growth backers include EW Healthcare Partners, HealthQuest Capital, Longitude Capital, Aperture Venture Partners, SEDCO and Masters Special Situations. Cash financings, closed preferred tranches and debt draws are recorded separately from secondary purchases, debt-to-equity exchanges and unexercised warrants.

Dessn develops an AI-assisted design and prototyping platform that turns an existing product codebase into a collaborative visual workspace. Designers, product managers and engineers can explore interface variants using their real components and design systems, share working prototypes and export code for engineering review. Its cloud environment removes the local development setup needed to run a codebase, allowing product teams to work together around the same source of truth.

MSP Corp is a Canadian managed IT services provider that operates a national network of regional service teams and acquires independent managed service providers. It remotely manages IT infrastructure, cloud environments and cybersecurity for small and midsize businesses, with services including end-user support, monitoring, backup and disaster recovery, data governance and Microsoft cloud integration. Its managed AI services help organizations deploy Microsoft Copilot, build secure AI agents and retrieval-based systems, automate workflows, and manage AI governance, adoption and operating costs. The current group combines the MSP Corp platform and Groupe Access following their 2023 merger. Niobrara Capital announced its acquisition of the business in September 2026 for undisclosed terms.

Founding engineer at Ewake, designing, building and operating scalable and resilient systems.

AI scientist at Ewake, translating research into production software for site reliability engineering.

Co-founder of Dessn. Previously head of product at Planned; she and Nim Cheema have built products together since their early startup careers.

Founding design engineer at Dessn, building AI interfaces, agents and user interfaces. Previously at Rombo, where he developed tailwindcss-motion.

Leads growth at Dessn. Previously worked with co-founders Gabriella Hachem and Nim Cheema at Planned; brings B2B marketing experience spanning positioning, go-to-market strategy and events.

Founding engineer at Ewake, combining cognitive science and AI engineering.

Works in business operations at Ewake, building the processes supporting the company’s growth.

Co-founder of Dessn. Previously head of AI at Unsplash; builds the company’s AI design and prototyping platform with Gabriella Hachem.

Co-founder and CTO of Ewake. Previously worked on site reliability at Criteo; the UK investor also refers to him as Omid Gosha.

Co-founder and CEO of Ewake, focused on architecture and production reliability. Previously a site reliability engineer at Criteo.

Co-founder and former CEO of the MSP Corp platform. The company’s May 2, 2023 merger announcement appointed him chief mergers and acquisitions officer; continued service in that role after the 2026 acquisition is not verified.

Founding engineer at Ewake, developing software to address technical production challenges.

Chief of staff at Dessn, helping the company scale and prepare for its next growth stage. Previously worked with the Antler NYC team.

Madryn Asset Management, LP is a New York healthcare alternative investment manager launched in 2017. It provides structured debt, tailored credit and selected equity financing to commercially validated healthcare growth companies, combining clinical research with financial analysis and operational support. Its portfolio spans medical devices, therapeutics, diagnostics, life-science tools and healthcare technology and services. Neuroscience exposure includes transcranial magnetic stimulation through Neuronetics and Greenbrook TMS and minimally invasive neurosurgery through Monteris Medical; AI-enabled healthcare operations and virtual care are also areas of interest. Managing Partner Avinash Amin is a physician, and the published team includes investment, finance, legal, operations and scientific policy leaders. Madryn Health Partners and Select Opportunities are investment vehicles, distinct from the management partnership and fund administration entities. Walter Global Asset Management acquired a minority interest in the manager in January 2024, separately from investments in healthcare portfolio companies. Portfolio listings establish an investment relationship without automatically proving equity ownership, a specific financing round, or a fully drawn loan commitment.

Physician and Managing Partner of Madryn Asset Management, LP. Before forming Madryn he led healthcare structured debt, growth equity and royalty investments as a Visium partner from 2014 to 2017, and previously led healthcare investing at Siguler Guff from 2009 to 2014. He earned an MD, MHA and BA in classics at Washington University in St. Louis, completed his medical residency there and is board certified in internal medicine. His current manager biography describes earlier work heading Summit Strategies Group’s private equity advisory business and as chief clinical officer of Novactyl. Avinash Amin is a Neuronetics director and Madryn Asset Management managing partner, with prior healthcare investing leadership at Visium and Siguler Guff. This institutional board position does not establish a personal investment.

Merlin Cyber provides cybersecurity integration and go-to-market services for U.S. federal, defense, state, local and education customers and regulated enterprises. It evaluates and combines established and emerging vendors’ products into solutions for security operations, identity and access management, ransomware protection, zero-trust modernization and preparation for post-quantum cryptography. Its services help vendors meet public-sector requirements and reach government buyers, including through FedRAMP acceleration offered with the CGC affiliate. Merlin Cyber is the go-to-market and zero-trust modernization affiliate of Merlin Group; Merlin Ventures is a separate venture investing affiliate. Niobrara Capital lists Merlin Cyber as a current investment, and Hauser Private Equity confirms co-investment support.

Leads legal, compliance, risk and administrative functions, with government and technology-industry legal experience.

Leads federal deal operations, pricing and contract-vehicle strategy; previously worked at Accenture.

Founded Merlin and leads the group’s strategy; previously served in the U.S. Navy and aerospace technology roles.

Leads revenue, sales, partnerships and customer success, with prior technology sales experience at IBM and Oracle.

Cybersecurity and organizational transformation leader with prior experience at Accenture Federal Services.

Former senior CISA cybersecurity official, supporting delivery of cybersecurity technologies to government and critical industries.

Leads cybersecurity architecture and engineering services; previously held a federal technology leadership role at VMware.

Cybersecurity marketing executive with experience at Tenable, Thycotic and Cofense.

Leads Merlin Cyber’s data resilience business unit, with prior IBM and Veeam federal market experience.

Accelerates technology partner revenue across Merlin’s affiliates; previously worked at Gartner and IBM. This is the cybersecurity executive, distinct from the actress.

Also known as Bob Costello; former CISA chief information officer, now leading digital strategy and enterprise AI implementation.

Supports federal sales and cybersecurity growth strategy, with experience at Palo Alto Networks, CGI and Northrop Grumman.

GridBeyond develops AI software and energy-market services that optimise distributed electricity assets, including batteries, renewable generation, industrial loads and electric-vehicle charging. Its platform combines forecasting, automated dispatch, virtual power plants and trading to coordinate these assets with grid services and wholesale markets. Customers use it to manage energy costs, earn flexibility revenues and operate battery and renewable portfolios across assets behind and in front of the electricity meter.

Molecular Glue Labs is a UK biotechnology company developing AI infrastructure to discover and design molecular glues: small molecules that change protein-protein interactions and reprogram cellular protein networks. Its research combines computational biology with wet-lab experiments to pursue therapeutic approaches for disease targets that conventional drug discovery has difficulty addressing. Incorporated as Molecular Glue Labs Ltd in February 2024, it began operations in early 2025.

Noventiq is a London-headquartered global provider of digital transformation and cybersecurity services. It integrates enterprise software, cloud infrastructure, managed services and its own solutions for customers across emerging growth markets, including India and the Middle East. Its services include cloud migration, application and database modernization, IT asset and cloud cost management, security, data analytics and enterprise AI. Its Noventiq Global AI Solutions subsidiary develops AI and machine-learning systems, cloud automation, intelligent workspaces and AI-based video cataloging. Niobrara Capital made an undisclosed strategic equity investment in October 2025 alongside existing shareholders to support growth.

Supports GridBeyond’s marketing and presales activities through data acquisition, lead generation and CRM management.

Electrical engineer with industrial automation experience, including field and project engineering at Rockwell Automation.

Develops GridBeyond’s North American relationships in demand response, distributed energy and sustainability analytics.

Produces energy-market and commercial content; previously worked in publications and marketing at Cornwall Insight.

Energy-transition investor at Mirova with earlier experience helping build Eren’s renewable-energy business.

Finance and energy executive with previous leadership, corporate finance and business-transformation responsibilities at Mainstream Renewable Power.

Energy-transition investor and Klima Energy Transition Fund managing partner; formerly worked at Equinor Ventures and Demeter Partners.

Co-founder of ai-coustics and named legal representative of ai-coustics GmbH alongside Fabian Seipel. His engineering background includes machine-learning acoustic analysis for predictive train maintenance.

Co-founder, CEO and director of Molecular Glue Labs. His scientific background includes doctoral research at NYU Grossman School of Medicine on ubiquitin ligases and cell-cycle control. Companies House lists him as an active director appointed in February 2024.

Managing partner at Da Vinci Capital; reported Noventiq board member in the investor’s October 2025 release.

Sales and business-development professional with experience in renewable generation, engineering and Irish demand-response markets.

CEO and co-founder of ai-coustics. An audio and machine-learning engineer who founded the company in Berlin in 2021.

Software developer working on GridBeyond’s research and development systems with extensive programming and computing-platform experience.

Technology marketing executive with experience at IBM, NetBotz, APC and RF Code.

Climate-technology investor at Energy Impact Partners with previous energy research and strategy experience at BloombergNEF.

Also known as Jerry Letter; technology finance executive with prior roles at Corner Ventures, Airbnb and InterMedia Partners.

Energy engineer supporting customer proposals, Irish grid compliance, testing and company-wide ISO documentation.

Data scientist developing energy-price forecasting tools, with computational science and computer science training from UCD.

Human-resources leader with experience in technology, security, pharmaceutical and gaming businesses.

Accounting leader with prior controller and finance roles at Chatsworth Products, Supercircuits, Cerilliant and Accurate.

EDP Inovação executive with responsibility for corporate venture capital and startup engagement.

Joined Noventiq in 2026 to lead global execution and operating capabilities.

Commercial energy professional supporting data-driven sales operations and collaboration across sales, marketing, trading and product teams.

Klima energy-transition investment professional with previous finance experience at JPMorgan and Alantra.

Commercial leader with experience in energy risk management, demand response, business development and international growth.

GridBeyond co-founder and CEO with earlier automation, electronics and energy-sector experience at Philips, Microsol, PCAS and Duolog.

Energy-business executive with experience at EDP and McKinsey, including business transformation and distributed solar.

Systems architect developing software for distributed customer assets, virtual power plants and grid services.

Manufacturing and supply-chain executive with prior leadership experience at Zebra Technologies, Getac, Gateway, Compaq and Motorola.

Business-development professional with business and financial-management training and an interest in energy sustainability.

Business-development professional with experience in environmental and financial services, fintech and SaaS.

Scientific advisory board member of Molecular Glue Labs, disclosed in a February 2026 research publication. A structural biologist at the University of Washington and Howard Hughes Medical Institute investigator whose work includes ubiquitin ligases and molecular glues.

GridBeyond co-founder and technology leader developing demand response, frequency response and smart-tariff optimisation platforms.

IT support and service-delivery professional with experience across telecommunications, banking, logistics, aviation and energy.

Former chief executive of Kantar Insights; appointed to Noventiq’s board in October 2025. Current secondary directories classify this appointment as former, but a primary departure date was not recovered.

Chartered accountant and GridBeyond deputy CEO with a background in financial management, transactions and asset management.

Also known as Bob Foresman; former vice chairman of UBS Investment Bank.

Leads GridBeyond’s North American team and product development for AI solutions serving energy assets on both sides of the meter.

Director supporting GridBeyond’s UK northern-region customers, with renewable energy, demand response and power-quality experience.

Data engineer with data-modelling and warehousing experience, previously at Nissan Digital.

Head of machine learning and co-founder of ai-coustics, working on voice activity detection and speech enhancement models.

Active director of Molecular Glue Labs Ltd, appointed May 2, 2024.

International technology executive and former chief executive of Crayon Group.

Marketing and communications leader with experience translating technical products into energy-sector marketing programmes.

Ava develops AI speech recognition and live-captioning software that makes conversations accessible to Deaf and hard-of-hearing people. Its mobile, desktop and web applications caption in-person conversations and online meetings, identify speakers and support translation and text-to-speech. Ava Scribe combines automated captions with human transcription professionals. The company sells accessibility services to workplaces, schools, healthcare providers and other organizations, alongside consumer plans.

Green Revolution Cooling (GRC) designs single-phase liquid immersion cooling systems for data centers running AI, high-performance computing, cloud and edge workloads. Its ICEraQ rack systems and ICETank container solutions submerge server equipment in nonconductive ElectroSafe fluids, circulating liquid to remove heat. GRC also provides SystemManager monitoring and support for deploying and operating immersion-cooled infrastructure.

Interhuman AI develops multimodal AI models and developer infrastructure that identify observable social signals in speech, facial expressions and body language. Its Inter-2 models analyse aligned video, audio and text to help applications interpret conversational behaviour; Inter-2 Audio focuses on speech. The Copenhagen company combines behavioural science and machine learning for use in training, customer conversations, research interviews, meeting tools and robotics.

Medisola develops personalized nutrition and care-food solutions, including prepared meals designed for different life stages and dietary requirements such as diabetes and kidney disease. Its Recipe Design engine uses AI and nutrition data to design, analyze and adapt recipes, and its NUTRi-Solution services combine food products, nutrition management software and catering. The company works with clinicians and clinical nutritionists to study its meal plans. MEDI.SOLA, BAL:N and SOLA serve different consumer markets.

Mindset Care combines AI-assisted application tools with disability attorneys and case managers to help people obtain Social Security disability benefits. It handles SSI and SSDI eligibility intake, application paperwork, medical-record collection, appeals and representation, and provides a client portal for case updates and document uploads. The service supports people with mental illnesses, physical disabilities and other qualifying conditions, along with caregivers, and charges no upfront fee.

Neubility develops and operates autonomous robots for last-mile delivery, patrol and industrial tasks. Its camera-based AI navigation technology, NeuOn robotics kit and Neubility Control Center connect robot hardware with mission monitoring, remote response and fleet operations through a robot-as-a-service model. Its products include wheeled delivery and patrol robots, and it is developing humanoid and quadruped solutions with partners including Unitree. The business focuses on physical AI and robotics.

PSV Tech invests in Nordic software and AI companies at pre-seed and seed, before product-market fit. It backs small founding teams and helps them turn early technical or commercial proof into a repeatable business and prepare for later funding. PSV Tech launched in 2020 within the DTU-rooted PSV venture house and operates independently from PSV Foundry and the deep-tech investor PSV Hafnium. PSV Tech Management ApS (CVR 41398302) is the disclosed manager of PSV Tech Fund II K/S (CVR 45184749).

Has a background in mental health and human services and extensive experience processing Social Security disability claims.

The current company careers page publishes this team lead as 김병철. The ASCII creation name is a research transliteration, not an asserted official English spelling.

MEDI.SOLA CAIO. The company publishes his Korean name as 임정준 and identifies expertise in mathematics, physics and AI.

The current company careers page publishes this team lead as 박창현. The ASCII creation name is a research transliteration, not an asserted official English spelling.

Founded Mindset after encountering difficulty helping a loved one with schizophrenia apply for disability benefits.

MEDI.SOLA co-CEO and CIO; his work combines biotechnology and management.

Works on sensor fusion for autonomous robot perception. The company’s December 2024 interview publishes this given name only; no surname is inferred.

Resolves robot hardware issues at operating sites. Role and work are described in the company’s interview published December 19, 2024; no later complete employee roster is published.

The current company careers page publishes this team lead as 정기백. The ASCII creation name is a research transliteration, not an asserted official English spelling.

Works on backend architecture, roadmap coordination and code reviews. Role and work are described in the company’s interview published December 19, 2024; no later complete employee roster is published.

MEDI.SOLA CRO and head of its nutrition research institute. Previously led the nutrition team at Severance Hospital.

Company careers interview identifies 김형진 as an early team member working on robot perception. Creation name is a transliteration, not an official English spelling.

Technology entrepreneur directing GRC’s global business development; formerly served on its board.

Researches and develops deep-learning models for robot perception. Role and work are described in the company’s interview published December 19, 2024; no later complete employee roster is published.

Works on global route planning and robot navigation maps. Role and work are described in the company’s interview published December 19, 2024; no later complete employee roster is published.

Family medicine physician and MEDI.SOLA CMO.

The current company careers page publishes this team lead as 정지은. The ASCII creation name is a research transliteration, not an asserted official English spelling.

Works on authentication, robot-order payments, monitoring and cloud infrastructure. Role and work are described in the company’s interview published December 19, 2024; no later complete employee roster is published.

Organizes and operates robot service deployments at customer sites. Role and work are described in the company’s interview published December 19, 2024; no later complete employee roster is published.

Cooling and infrastructure technologist, formerly a Schneider Electric engineering leader and co-chair of the OCP Immersion Committee.

Published on the company careers interview directory as 이주광. The creation name is a transliteration; no official English spelling is asserted. Older interview describes an earlier field-operations leadership role.

MEDI.SOLA CPO, working on service planning.

NEUBILITY CEO, identified in the company’s July 2026 Unitree partnership announcement and current careers site. Older careers interviews identify him as vice president; the latest announcement confirms the CEO role.

Leads nationwide expansion and partnerships, with a background in venture capital and finance.

Former fractional CFO who joined Mindset in-house to lead financial planning and analysis.

Works on making deep-learning perception models lightweight. Role and work are described in the company’s interview published December 19, 2024; no later complete employee roster is published.

Social Security law specialist with over a decade of experience in client advocacy.

Listed as director and secretary of Mindset Care, Inc. in the current West Virginia Secretary of State corporate record.

Data-center technology executive whose earlier roles included Compaq, APC, Schneider Electric and NetBotz.

Historically served as Ava COO. A current operational title or board appointment has not been independently verified.

Develops computer-vision detection models and uses generative AI for data augmentation. The company’s December 2024 interview publishes this given name only; no surname is inferred.

MEDI.SOLA co-CEO with a background in food and spaces. She initiated the nutrition project with Hyung-mi Kim in 2016.

Has experience working with the Social Security Administration and Department of Social Services.

Deaf since age two; co-founded Ava and leads its captioning technology.